Details for Patent: 12,280,025
✉ Email this page to a colleague
Which drugs does patent 12,280,025 protect, and when does it expire?
Patent 12,280,025 protects LODOCO and is included in one NDA.
This patent has forty-eight patent family members in twenty-four countries.
Summary for Patent: 12,280,025
| Title: | Treatment or prevention of cardiovascular events via the administration of a colchicine derivative |
| Abstract: | A method for reducing a composite endpoint risk of myocardial infarction (MI), stroke, coronary revascularization, unstable angina requiring hospitalization, cardiac arrest, and cardiovascular death in a subject including administering, orally once per day to the subject, a composition comprising about 0.5 total mg of (i) colchicine, (ii) a pharmaceutically acceptable salt of (i), or any combination of (i) and (ii), wherein the patient has at least one history of diabetes, a past myocardial infarction, an unstable angina, a coronary bypass surgery, and a coronary angioplasty; wherein the patient is also administered a daily dose of statin therapy; and wherein the composite endpoint risk in the subject is reduced relative to a dosing regimen where the patient receives standard secondary prevention therapy of a statin. |
| Inventor(s): | Mark Nidorf |
| Assignee: | Murray and Poole Enterprises Ltd |
| Application Number: | US18/367,412 |
| Patent Litigation and PTAB cases: | See patent lawsuits and PTAB cases for patent 12,280,025 |
|
Patent Claim Types: see list of patent claims | Use; Composition; Formulation; Delivery; Dosage form; |
Drugs Protected by US Patent 12,280,025
| Applicant | Tradename | Generic Name | Dosage | NDA | Approval Date | TE | Type | RLD | RS | Patent No. | Patent Expiration | Product | Substance | Delist Req. | Patented / Exclusive Use | Submissiondate |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Agepha Pharma Fz | LODOCO | colchicine | TABLET;ORAL | 215727-001 | Jun 16, 2023 | RX | Yes | Yes | 12,280,025 | ⤷ Start Trial | A METHOD FOR REDUCING A RISK OF AT LEAST ONE CARDIOVASCULAR EVENT | ⤷ Start Trial | ||||
| >Applicant | >Tradename | >Generic Name | >Dosage | >NDA | >Approval Date | >TE | >Type | >RLD | >RS | >Patent No. | >Patent Expiration | >Product | >Substance | >Delist Req. | >Patented / Exclusive Use | >Submissiondate |
International Family Members for US Patent 12,280,025
| Country | Patent Number | Estimated Expiration | Supplementary Protection Certificate | SPC Country | SPC Expiration |
|---|---|---|---|---|---|
| Australia | 2013337605 | ⤷ Start Trial | |||
| Australia | 2018203715 | ⤷ Start Trial | |||
| Australia | 2019232879 | ⤷ Start Trial | |||
| Australia | 2021282491 | ⤷ Start Trial | |||
| Australia | 2024205084 | ⤷ Start Trial | |||
| >Country | >Patent Number | >Estimated Expiration | >Supplementary Protection Certificate | >SPC Country | >SPC Expiration |
